Abstract:Protein levels and function are predicted poorly by genomic and transcriptomic analysis of patient tumors. Direct proteomic study can provide a wealth of information that complements those analysis in The Cancer Genome Atlas (TCGA) projects. We used reverse-phase protein arrays to analyze 3,467 patient samples from 11 TCGA “Pan-Cancer” diseases, using 181 high-quality antibodies that target 128 total proteins and 53 phospho-proteins. The resultant proteomic data were used for identifying commonalities, differences, emergent pathway properties, and novel network biology within and across tumor lineages. In general, tumor type and subtype were the dominant determinants of protein levels. However, we were able to identify several potentially targetable markers. E.g. luminal breast cancers demonstrated selective elevation of AR, BCL2, FASN, and pACC. SRC was activated in all but the hormone-responsive and bladder cancers, offering another potential therapeutic opportunity. Similarly, HER3 suggested itself as a potential target in renal cancer. EGFR activity, in general, paralleled SRC activity, but in GBM it was associated with NOTCH1 and HER3 activation, suggesting an opportunity for combination therapy. pSRC was highly expressed in a subset of head and neck tumors, suggesting that those may be more sensitive to EGFR targeting strategies. HER2 levels were elevated in a subset of endometrial, bladder, breast, and colorectal cancers. MYC was selectively amplified and expressed in high-grade serous ovarian cancers. We implemented a computational approach, MC, to decrease the effect of tissue-specific protein expression. MC allowed us to identify processes that drive cell behavior across tumor type and made it possible to find new therapeutic opportunities. We found 7 cross-tumor clusters, each driven by different markers and pathways. We found pan-cancer clusters with elevated HER2 and EGFR, elevated hormone signaling pathways, enriched MAPK and PI3K pathway activity, elevated EMT signatures, and cell cycle signatures. We also saw strong links between MYH11 and Rictor and between ETS1 and pPEA15 across tumor types. Those findings can provide useful clues for developing targeted, cross-tumor therapies. Pathway analysis of the data revealed several expected cross-tumor type associations, including pMEK with pERK, beta-catenin with E-cadherin and pPKCdelta with pPKCalpha and pPKCbeta. The findings support the ability of RPPA analysis to yield high-quality information from TCGA samples. A number of other links such as MYH11 with Rictor, cyclinB1 with FOXM1, and pACC with FASN were not expected and warrant further exploration, as does a negative link between p85 and claudin7 in lung squamous. Analysis of key nodes (e.g., CDK1) revealed other unexpected links to a wide range of protein pathways. Overall, those findings demonstrate the power of pan-cancer proteomic analysis, identifying several novel single-tumor and cross-tumor targets and pathways. Citation Format: Rehan Akbani, Kwok-Shing Ng, Henrica M. Werner, Fan Zhang, Zhenlin Ju, Wenbin Liu, Ji-Yeon Yang, Yiling Lu, John N. Weinstein, Gordon B. Mills. A pan-cancer proteomic analysis of The Cancer Genome Atlas (TCGA) project. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4262. doi:10.1158/1538-7445.AM2014-4262

Abstract 1852: NCI's Clinical Proteomic Tumor Analysis Consortium: A proteogenomic cancer analysis program

Abstract 2019: NCI’s clinical proteomic tumor analysis consortium analysis tools and resources

A Description of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Common Data Analysis Pipeline

Abstract 4262: A pan-cancer proteomic analysis of The Cancer Genome Atlas (TCGA) project

Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays.

Proteogenomic data and resources for pan-cancer analysis

Abstract 5726: Pan-cancer Proteogenomics Expands the Landscape of Therapeutic Targets

Abstract 6241: A large scale proteogenomic atlas for precision oncology research

Abstract IA29: Proteogenomic and phosphoproteomic analysis of breast cancer

Abstract 1851: Comprehensive multi-level proteomics characterization of gastric cancer

Abstract 6915: Integrated proteogenomic analysis for the NCI patient-derived cancer model repository

Abstract 4931: The Cancer Proteome Atlas: Expanded datasets and empowered with an AI-driven chatbot

Abstract 4897: Personalized cell surface target identification from pan-cancer RNA-seq and proteomics profiling of tumors

Abstract 6563: PSMA-based detection and global proteome-based analysis of circulating tumor cells in castration resistant prostate cancer patients

An Integrated Tool for Multi-Dimensional Cancer Research Utilizing Clinical Proteomic Tumor Analysis Consortium Data

Abstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia

Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy

Abstract LB012: Evaluating computational approaches for CPTAC pan-cancer cross-cohort protein expression comparison

PCAS: an Integrated Tool for Multi-Dimensional Cancer Research Utilizing Clinical Proteomic Tumor Analysis Consortium Data

Pan-cancer proteogenomics expands the landscape of therapeutic targets

NCI's Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data